Postcoital or emergency contraception is a way of using proven methods of birth control to prevent a pregnancy within 3 to 7 days of the last act of unprotected or unintended intercourse. The contraceptive methods that can be used can be either hormonal (estrogens, oral contraceptives, danazol, or RU486) or mechanical (intrauterine device [IUD] ). The exact mechanism of action with any of these agents is probably dependent on the occurrence of ovulation in relation to the timing of intercourse and the subsequent use of the contraceptive agent.
Because the Food and Drug Administration approved postcoital contraception (PCC) in the form of combination oral contraceptives or progestin-only pills, an effort has been made to educate patients and physicians on its potential use. If PCC is used when a couple is at risk for an unintended pregnancy, half of the estimated 3.5 million unintended pregnancies could be prevented. 1 The only contraindication to most methods of PCC is an ongoing pregnancy. Situations in which PCC should be considered are listed in Table 1 .
In 1995, a consensus statement was published that was sponsored by Family Health International, the Population Council, International Planned Parenthood Foundation, and the World Health Organization. 2 This group of 24 experts identified three hurdles that must be overcome to make PCC available to all women:
1. Inform patients and doctors about PCC so that women know about it before they need it. 2. Have pharmaceutical companies that make appropriate contraceptive agents that can be used for PCC publicize these methods and provide adequate information. 3. Postcoital contraception is probably underused by health care providers because it may be thought of primarily as an abortifacient, instead of as a way to prevent an unwanted pregnancy. Estrogens, combination oral contraceptive pills, progestin-only pills, and danazol probably act in different ways to prevent a pregnancy, depending on when the method is administered. If administered before ovulation, disruption of follicular growth, development, and maturation is noted. 3 This disruption can lead to anovulation or delayed ovulation with a change in hor-moneproduction during the luteal phase of the menstrual cycle. Postovulatory treatment probably has an effect on the endometrium. However, these methods cannot hamper an ongoing pregnancy.
Estrogens
Initially, the estrogen components of ovarian extracts were used in the 1920s for their ability to prevent pregnancies. 4 Ethinyl estradiol (EE), diethylstilbesterol, and conjugated estrogens have been used for PCC with good results. Fasoli et al 5 analyzed four studies that used EE at daily doses that ranged between 2 and 5 mg for 5 days. The cumulative pregnancy rates from these studies was 0.6%.
Diethylstilbesterol and conjugated estrogens also demonstrated low failure rates (0.7% and 1.6%, respectively). 6, 7 Of these three estrogen compounds, diethylstilbesterol was the most widely used as a PCC until the relationship between its use in early pregnancy and the teratogenic effects found in the female offspring was discovered. No such adverse effects have been noted with the use of EE or conjugated estrogens.
In comparison to combination oral contraceptive pills for PCC, any of the estrogen-alone protocols show a lower failure rate. However, the incidence of side effects in the estrogen users was more severe. These side effects included a higher percentage of patients with nausea, emesis, breast tenderness, irregular bleeding, and pulmonary edema. Because the estrogens were administered for a prolonged period of time, and because the side effects were thought to be dose-dependent, health care providers were in search of other methods that would decrease symptoms of side effects and increase compliance.
Oral Contraceptives

COMBINATION PILLS
In 1977, Yuzpe and Lancee 8,9 published their first article that showed that 200 g of EE and 2 g of levonorgestrel in two divided doses over the course of 12 hours within 72 hours of unprotected intercourse. The primary advantage of this regime, which came to be known as the "Yuzpe method," is a 125-fold reduction in EE content and a decrease in overall length of drug administration. In this landmark study, 608 women were treated, though 464 admitted to regular menstrual cycles and only 152 had unprotected intercourse at the midcycle. One pregnancy was documented in a woman who was exposed at midcycle and started the medication 70 hours after intercourse. The pregnancy was terminated by vacuum aspiration and pathologic evaluation of the placenta revealed "fibrinoid necrosis of many of the chorionic villi." Though twothirds of the patients had nausea, only 19% admitted to emesis. 
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THOMAS Five years later, Yuzpe et al published a follow-up study that documented 11 pregnancies in 692 women who adhered to the previous protocol. Of this group, 451 patients were noted to have regular cycles. Of these women with regular cycles, 101 were exposed before the midcycle, 217 at midcycle, and 133 after the midcycle. Of the 11 pregnancies, nine were in women with regular cycles and two were in those with irregular cycles. In the women with regular cycles, no pregnancies were seen in those exposed after the midcycle. One pregnancy occurred in a woman who vomited after drug administration. Nausea and/or emesis occurred in 51.7% of all patients. Other side effects were minimal.
Other investigators using the Yuzpe method within 72 hours of exposure of intercourse had a pregnancy rate of 2.2%. Those who administered the same dose of drug up to 130 hours had a failure rate of 2.4%.
PROGETIN-ONLY PILLS
Pills containing levonorgestrel have been shown to be just as effective as the Yuzpe method for PCC. Ho and Kwan 10 randomized 424 women to use the Yupze method and 410 to the levonorgestrel group. The levonorgestrel is administered as one 0.75-mg tablet within 72 hours of intercourse exposure and repeated in 12 hours. Though 18.2% of the combination pill users and 19.3% of the progestin-only pill users continued to have intercourse during the treatment cycle, only 3.5% of the Yuzpe group and 2.9% of the levonorgestrel group became pregnant. When compared with the Yuzpe method, the progestin-only regimen is just as effective with significantly less symptoms of nausea, emesis, or breast tenderness caused by the lack of estrogen. Currently, both combination oral contraceptive pills (Preven) and progestin-only pills (Plan B) are approved by the Food and Drug Administration for PCC use.
DANAZOL
Danazol is an androgen analogue that primarily has been used in doses ranging from 400 to 800 mg for patients with endometriosis to induce a pseudomenopausal state. Studies concerning the effectiveness of danazol as a PCC have not been encouraging. Three investigators have demonstrated that danazol 800 mg, when used up to 120 hours after intercourse, conferred pregnancy rates ranging from 2.1-7.7%. 5 When the dose of danazol was increased to 1,200 mg over the course of 12 hours, the pregnancy rates narrowed to 0.9 -4.7%. 5 Though the incidence of nausea and emesis were lower than that seen with the Yuzpe method, the effectiveness of danazol as a PCC was unacceptable.
INTRAUTERINE DEVICE
The copper-containing IUD has been shown to be an effective method of PCC and can be used up to 7 days after exposure. The exact mechanism of action is not entirely known, but it is theorized that the IUD may have an effect on tubal cilial motility to disrupt transport of an oocyte or embryo. The IUD itself or its copper ions may also hamper the ability of an embryo to implant. The latter feature may contribute to its effectiveness many days after intercourse has taken place.
The copper IUD for PCC was first described in 1976. 11 Since that time, the failure rate with this device has been consistently Ͻ0.1% in most studies. 5 The primary side effect associated with this method is the same noted with normal IUD insertions, which include the possibility of uterine cramping and vaginal spotting or bleeding.
One of the biggest advantages of the IUD is that it can be used as an ongoing method of contraception. Therefore, it should not be used in patients who would not normally place the device, which includes women who have pelvic infections (acute, recent, or recurrent), pregnancy, distorted uterine cavity, or multiple sexual partners.
Though IUDs have been shown to be effective, they are not being used as frequently as they could. When physicians were polled concerning IUDs for PCC, they stated that they thought the obstacles of using the IUD were the possible risk for pelvic inflammatory disease or the amount of time it took to place the device. 12 This study demonstrated that physicians should become more comfortable with IUD use and should consider them in patients who have need for PCC.
RU486
Antiprogestins are a family of compounds that block the progesterone receptor. Because progesterone is important in the development of the endometrium, ovulation, and continuation of a pregnancy, any disruption to the progesterone receptor could lead to an adverse effect on follicular development, implantation, and pregnancy maintenance. The most commonly studied antiprogestin as a PCC is RU486 (mifepristone), though other agents in this class are currently being studied for this purpose.
When RU486 is administered for in a single 600-mg dose within 72 hours of intercourse, it is as efficacious as the Yuzpe method or danazol. In two studies that examined all three methods, the range of failure were RU486 (0 -0.4%), Yuzpe (1.3-2.6%), and danazol (3.5-4.7%). 13, 14 Also, compared with the Yuzpe method, patients using RU486 had low rates of nausea (70% vs 37%) and emesis (22% vs 3%). Though women using Yuzpe had a higher incident of irregular bleeding, those using RU486 were noted to delay their normal menses. Because of this delay, intercourse should be avoided and the patient reassured that a postponed cycle may not be secondary to a pregnancy. If menses has not occurred with 3 weeks, a pregnancy test should be performed.
Recently, RU486 was approved for use in the United States. It has been documented to have beneficial effects in the treatment of uterine fibroids, endometriosis, labor induction, cervical ripening, breast cancer, and meningiomas. 15 The use of RU486 as an effective single-dose PCC agent will help to increase patient compliance, decrease adverse symptoms, and therefore help to decrease the incidence of medical and surgical abortions and the social implications brought on by the delivery of an unwanted pregnancy.
Conclusion
The use of PCC as a repetitive method of contraception should be strongly discouraged. At the time of PCC administration, plans should be made to use an ongoing contraceptive pill or device and further acts of unprotected intercourse should be discouraged. A follow-up appointment 2 to 3 weeks after PCC use will allow the clinician to check for method failure and encourage contraceptive compliance.
To increase the use of PCC, both physicians and patients need to be educated about the agents that are available and their side effects. The "ideal" postcoital contraceptive is probably RU486 because it can be administered as a single dose to increase compliance, few side effects are noted, and it has the lowest failure rate.
